Clinical Trial Update: Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical study of a therapeutic immunological agent for Epstein-Barr virus-associated malignancies; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-associated Malignancies

Drugs mentioned

• Therapeutic Immunological Agent

Snippet

Sponsor: West China Hospital | Conditions: Malignant Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING